Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses

被引:26
作者
Gzy, J
Bolesta, E
Wierzbicki, A
Kmieciak, D
Naito, T
Honda, M
Komuro, K
Kaneko, Y
Kozbor, D
机构
[1] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA
[2] Univ Med Sci, Dept Biochem & Mol Biol, Poznan, Poland
[3] Juntendo Univ, Dept Gen Med, Tokyo 113, Japan
[4] Natl Inst Infect Dis, AIDS Res Ctr, Vaccine Res & Dev Grp, Tokyo 208, Japan
[5] Ajinomoto Co Inc, Div Pharmaceut, Tokyo 104, Japan
关键词
HIV-1; DNA vaccine; envelope glycoprotein; cellular responses; neutralizing antibodies;
D O I
10.1016/j.virol.2003.10.009
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Induction of cross-reactive cellular and Immoral responses to the HIV-1 envelope (env) glycoprotein was examined after DNA immunization of BALB/c mice with gp140(89.6)-derived constructs exhibiting partial or complete deletions of the VI, V2, and V3 domains. It was demonstrated that specific modification of the V3 loop (mV3) in combination with the V2-modified (mV2) or V1/V2-deleted (DeltaV1/V2) region elicited increased levels of cross-reactive CD8(+) T cell responses. Mice immunized with the mV2/mV3 or DeltaV1/V2/mV3 gp140(89.6) plasmid DNA were greater than 50-fold more resistant to challenge with recombinant vaccinia virus (rVV) expressing heterologous env gene products than animals immunized with the wild-type (WT) counterpart. Sera from mV2/mV3- and DeltaV1/V2/mV3-immunized mice exhibited the highest cross-neutralizing activity and displayed intermediate antibody avidity values which were further enhanced by challenge with rVV expressing the homologous gp160 glycoprotein. In contrast, complete deletion of the variable regions had little or no effect on the cross-reactive antibody responses. The results of these experiments indicate that the breadth of antibody responses to the HIV-1 env glycoprotein may not be increased by removal of the variable domains. Instead, partial deletions within these regions may redirect specific responses toward conserved epitopes and facilitate approaches for boosting cross-reactive cellular and antibody responses to the env glycoprotein. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:493 / 506
页数:14
相关论文
共 55 条
[1]   The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region [J].
Barnet, SW ;
Lu, S ;
Srivastava, I ;
Cherpelis, S ;
Gettie, A ;
Blanchard, J ;
Wang, S ;
Mboudjeka, I ;
Leung, L ;
Lian, Y ;
Fong, A ;
Buckner, C ;
Ly, A ;
Hilt, S ;
Ulmer, J ;
Wild, CT ;
Mascola, JR ;
Stamatatos, L .
JOURNAL OF VIROLOGY, 2001, 75 (12) :5526-5540
[2]  
Barouch DH, 1998, J IMMUNOL, V161, P1875
[3]   Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding [J].
Basmaciogullari, S ;
Babcock, GJ ;
Van Ryk, D ;
Wojtowicz, W ;
Sodroski, J .
JOURNAL OF VIROLOGY, 2002, 76 (21) :10791-10800
[4]   Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge [J].
Belyakov, IM ;
Derby, MA ;
Ahlers, JD ;
Kelsall, BL ;
Earl, P ;
Moss, B ;
Strober, W ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (04) :1709-1714
[5]   A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure [J].
Binley, JM ;
Sanders, RW ;
Clas, B ;
Schuelke, N ;
Master, A ;
Guo, Y ;
Kajumo, F ;
Anselma, DJ ;
Maddon, PJ ;
Olson, WC ;
Moore, JP .
JOURNAL OF VIROLOGY, 2000, 74 (02) :627-643
[6]  
BOGERS WM, 1995, AIDS, V9, P13
[7]   GENERATION OF HUMAN MONOCLONAL-ANTIBODIES AGAINST HIV-1 PROTEINS - ELECTROFUSION AND EPSTEIN-BARR-VIRUS TRANSFORMATION FOR PERIPHERAL-BLOOD LYMPHOCYTE IMMORTALIZATION [J].
BUCHACHER, A ;
PREDL, R ;
STRUTZENBERGER, K ;
STEINFELLNER, W ;
TRKOLA, A ;
PURTSCHER, M ;
GRUBER, G ;
TAUER, C ;
STEINDL, F ;
JUNGBAUER, A ;
KATINGER, H .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (04) :359-369
[8]   Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein [J].
Cao, J ;
Sullivan, N ;
Desjardin, E ;
Parolin, C ;
Robinson, J ;
Wyatt, R ;
Sodroski, J .
JOURNAL OF VIROLOGY, 1997, 71 (12) :9808-9812
[9]   Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization [J].
Chakrabarti, BK ;
Kong, W ;
Wu, B ;
Yang, ZY ;
Friborg, J ;
Ling, X ;
King, SR ;
Montefiori, DC ;
Nabel, GJ .
JOURNAL OF VIROLOGY, 2002, 76 (11) :5357-5368
[10]   Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques [J].
Cho, MW ;
Kim, YB ;
Lee, MK ;
Gupta, KC ;
Ross, W ;
Plishka, R ;
Buckler-White, A ;
Igarashi, T ;
Theodore, T ;
Byrum, R ;
Kemp, C ;
Montefiori, DC ;
Martin, MA .
JOURNAL OF VIROLOGY, 2001, 75 (05) :2224-2234